
Neuronetics Inc (STIM) Stock Forecast & Price Target
Neuronetics Inc (STIM) Analyst Ratings
Bulls say
Neuronetics is poised for continued success with its strong Q2 performance and strategic focus on improving margins and expanding its customer base through acquisitions and partnerships. However, potential competition and regulatory challenges could present risks in the future. The company's success in treating mental health conditions and its collaborations in the growing interventional psychiatry space set it up for long-term growth potential, particularly with the potential approval of COMP360 psilocybin therapy.
Bears say
Neuronetics is facing several challenges that could impact their profitability, including inconsistent commercial execution and a potential slowdown in procedure volumes. They have a history of operating losses and continue to burn significant amounts of cash, with $19M in cash at the end of Q1 and guidance implying an additional $6M in operating cash outflows for the remainder of the year. Their reliance on equity issuances and debt could also be a concern if they continue to struggle with profitability.
This aggregate rating is based on analysts' research of Neuronetics Inc and is not a guaranteed prediction by Public.com or investment advice.
Neuronetics Inc (STIM) Analyst Forecast & Price Prediction
Start investing in Neuronetics Inc (STIM)
Order type
Buy in
Order amount
Est. shares
0 shares